Abstracts Archive - Page 199 of 1683 - ATC Abstracts

2021 American Transplant Congress
The Use of Organs from Donors That Do Not Meet Eligibility Criteria in the United States
L. Deroos, M. Lavieri, D. Hutton, W. Marrero, N. Parikh
University of Michigan, Ann Arbor, MI
*Purpose: Increasing the number of organs available for transplantation could reduce waitlist morbidity and mortality for patients with end organ failure. Most transplanted organs come…
2021 American Transplant Congress
Impact of Covid-19 Infection on Tacrolimus Levels in Solid Organ Transplant Recipients
K. Heagler, K. Tejani, S. Sanchez
Loyola University Medical Center, Maywood, IL
*Purpose: Immunocompromised patients are considered to be at high-risk for infection with SARS-CoV-2 (COVID-19). There have been observations within the transplant community that patients infected…
2021 American Transplant Congress
Accounting for Survivor Bias in Transplant Benefit Models
E. M. Schnellinger¹, E. Cantu², M. O. Harhay¹, D. E. Schaubel¹, S. E. Kimmel¹, A. J. Stephens-Shields¹
¹Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²Department of Surgery, Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: The lung allocation system in the U.S. prioritizes lung transplant candidates based on estimated pre- and post-transplant survival. However, these models do not account…
2021 American Transplant Congress
Quantification of Multiple Isotypes of Anti-SARS-CoV-2 Antibodies in Kidney Transplant Recipients
J. S. Maltzman¹, L. Wang¹, P. Ahearn¹, T. Yalamarti¹, M. Menon², Y. Azzi³, M. Melcher¹, M. Fernandez-Vina¹, R. Bray⁴, H. Gebel⁴, E. Woodle⁵, E. Akalin³, A. Girnita¹, P. Cravedi²
¹Stanford University, Palo Alto, CA, ²Icahn School of Medicine, NYC, NY, ³Einstein School of Medicine, NYC, NY, ⁴Emory University, Atlanta, GA, ⁵University of Cincinnati, Cincinnati, OH
*Purpose: Solid organ transplant recipients are at increased risk of severe outcomes with infection by SARS-CoV-2, the etiologic agent of COVID-19. Antibodies directed against the…
2021 American Transplant Congress
Early Review of Liver Acuity Circles Allocation
S. Noreen¹, J. Heimbach², J. Pomposelli³, M. Cafarella¹, J. Trotter⁴
¹UNOS, Richmond, VA, ²Mayo Clinic, Rochester, MN, ³UCHealth, Aurora, CO, ⁴BSWHealth, Dallas, TX
*Purpose: Acuity circles (AC) allocation was implemented on February 4, 2020, followed shortly by the declaration of national emergency for COVID-19. The goal of this…
2021 American Transplant Congress
Nurse and Nurse Practitioner-lead Monoclonal Antibody Initiative for Solid Organ Transplant (sot) Recipients with Covid-19
W. Cochran¹, R. Avery², D. Brennan², N. Lawrence², A. Brown², S. Sullivan², B. Adams², M. McCarthy², S. Ellis², F. Naqvi², E. Kraus², N. Alachkar², S. Alasfar², F. Al Ammary², J. Horn², L. Hartman², L. Fessler², S. Purekal², Z. Siddiqui², D. Carter², J. Ficke², M. Kantsiper², L. Boyer², I. Gupta², A. Gurakar², D. Ostrander², J. Langlee², S. Shoham², K. Marr², P. Shah²
¹Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, ²Johns Hopkins, Baltimore, MD
*Purpose: Monoclonal antibody (mAB) infusion (bamlanivimab or casirivimab/imdevimab) for symptomatic, non-hypoxemic, high-risk outpatients with COVID-19 infection, is an available early intervention for COVID-19+ SOT recipients.…
2021 American Transplant Congress
High Levels of Sars-cov-2 Detected in Immunosuppressed Covid-19 Patient Environments Weeks Following Initial Positive Test
C. E. Kuschner¹, Z. Brune², L. B. Becker¹, L. Teperman¹
¹North Shore University Hospital, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY
*Purpose: COVID-19 is a novel viral illness associated with significantly worse mortality, prolonged disease course, and extended periods of viral shedding in transplant patients on…
2021 American Transplant Congress
Donor Derived Cell-Free DNA (dd-cfDNA) in Pancreas Transplant Recipients
S. Riad¹, H. Sarumi², R. Kandaswamy³
¹Medicine, University of Minnesota, Minneapolis, MN, ²Surgery, University of Minnesota Physicians, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Data on the role of DD-cfDNA after pancreas transplantation is lacking. Herein we report on our center experience with DD-cfDNA in 10 unique SPK…
2021 American Transplant Congress
One-Year Monitoring of Changes to Kidney-Pancreas Waiting Time Criteria: An OPTN Analysis
R. C. Forbes¹, B. Plucinski², J. White², N. T. Kyaw², R. Kandaswamy³, S. V. Niederhaus⁴
¹Surgery, Vanderbilt University, Nashville, TN, ²UNOS, Richmond, VA, ³Surgery, University of Minnesota, Minneapolis, MN, ⁴Surgery, University of Maryland, Baltimore, MD
*Purpose: In 2018, the OPTN board approved changes to kidney-pancreas (KP) waiting time criteria. KP candidates accrued waiting time if they were (1) on insulin…
2021 American Transplant Congress
Genetic versus Self-reported African Ancestry and Kidney Allograft Outcome: Analysis of Two Large Multiethnic Urban Transplant Cohorts
F. Zanoni¹, D. Neugut¹, S. Mohan¹, A. Gharavi¹, B. Keating², K. Kiryluk¹
¹Department of Medicine, Division of Nephrology, Columbia University, New York, NY, ²Department of Surgery, Division of Transplantation, University of Pennsylvania, Philadelphia, PA
*Purpose: African-American (AA) kidney transplant recipients (KTx) have higher risk of rejection and failure. However, it is unknown to what extent the inferior outcomes in…